Experienced in Lymphofollicular Hyperplasia

Dr. Efrat Dotan

Hematology | Oncology
Penn Medicine
LG Health Physicians Hematology And Medical Oncology
2102 Harrisburg Pike, 
Lancaster, PA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients

Experienced in Lymphofollicular Hyperplasia
Penn Medicine
LG Health Physicians Hematology And Medical Oncology
2102 Harrisburg Pike, 
Lancaster, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Efrat Dotan is a Hematologist and an Oncologist in Lancaster, Pennsylvania. Dr. Dotan is rated as an Experienced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Cholangiocarcinoma (Bile Duct Cancer). Dr. Dotan is currently accepting new patients.

Her clinical research consists of co-authoring 95 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Technion - Israel Institute Of Technology
Residency
Lenox Hill Hospital
Specialties
Hematology
Oncology
Licenses
Internal Medicine in PA
Board Certifications
Medical Oncology, 2010
Fellowships
Fox Chase Cancer Center
Hospital Affiliations
Lancaster General Hospital
Temple University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

LG Health Physicians Hematology and Medical Oncology
2102 Harrisburg Pike, Lancaster, PA 17601
Call: 717-544-9400

Additional Areas of Focus

Dr. Dotan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Esophageal Cancer
Gallbladder Cancer
Pancreatic Cancer
Colorectal Cancer
Anal Cancer
Liver Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

Window of Opportunity for Neoadjuvant Stroma Modification in Pancreatic Cancer
Window of Opportunity for Neoadjuvant Stroma Modification in Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: April 16, 2025
Intervention Type: Other, Combination product
Study Phase: Early Phase 1
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Redefining The Use Of A FOLFIRINOX-Like Regimen In the Front Line In Older Patients With Metastatic Pancreatic Cancer
Redefining The Use Of A FOLFIRINOX-Like Regimen In the Front Line In Older Patients With Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug
Study Phase: Phase 2
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drug: ZW49
Study Phase: Phase 1
Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study
Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
Enrollment Status: Terminated
Publish Date: January 24, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas
A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: April 25, 2023
Intervention Type: Drug
Study Drugs: Adavosertib, Gemcitabine hydrochloride, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors
A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 2
Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient Via a Provider Didactic Intervention
Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient Via a Provider Didactic Intervention
Enrollment Status: Completed
Publish Date: March 02, 2020
Intervention Type: Behavioral
Study Phase: Not Applicable
Phase I Study of Drug-Eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-Only or Liver-Predominant Disease
Phase I Study of Drug-Eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-Only or Liver-Predominant Disease
Enrollment Status: Terminated
Publish Date: February 26, 2018
Intervention Type: Procedure, Combination product
Study Phase: Phase 1
View 13 Less Clinical Trials

95 Total Publications

Prioritizing Benefit Over Tolerance Among Older Adults With Pancreatic Cancer.
Prioritizing Benefit Over Tolerance Among Older Adults With Pancreatic Cancer.
Journal: JCO oncology practice
Published: December 15, 2025
View All 95 Publications
Similar Doctors
Nina Wagner
Distinguished in Lymphofollicular Hyperplasia
Dr. Nina Wagner
Oncology | Hematology
Distinguished in Lymphofollicular Hyperplasia
Dr. Nina Wagner
Oncology | Hematology

Sidney Kimmel Comprehensive Cancer Center

Baltimore, MD 
 (55.5 miles away)
410-955-8964
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Elite provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Distinguished in Lymphofollicular Hyperplasia
Dr. Michael R. Costello
Hematology | Oncology
Distinguished in Lymphofollicular Hyperplasia
Dr. Michael R. Costello
Hematology | Oncology

Abramson Cancer Center Exton

700 West Lincoln Highway, Suite 720,The Commons At Oaklands, 
Exton, PA 
 (37.9 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Costello is a Hematologist and an Oncologist in Exton, Pennsylvania. Dr. Costello is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Lymphofollicular Hyperplasia, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Iron Deficiency Anemia. Dr. Costello is currently accepting new patients.

Distinguished in Lymphofollicular Hyperplasia
Dr. Sandra F. Schnall
Hematology Oncology | Hematology | Oncology
Distinguished in Lymphofollicular Hyperplasia
Dr. Sandra F. Schnall
Hematology Oncology | Hematology | Oncology
825 Old Lancaster Rd, Suite 320, 
Bryn Mawr, PA 
 (54.8 miles away)
610-527-3800
Languages Spoken:
English
See accepted insurances

Sandra Schnall is a Hematologist Oncology specialist and a Hematologist in Bryn Mawr, Pennsylvania. Dr. Schnall is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, Breast Cancer, and Bone Marrow Aspiration.

VIEW MORE LYMPHOFOLLICULAR HYPERPLASIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dotan's expertise for a condition
ConditionClose
  • Elite
  • Colorectal Cancer
    Dr. Dotan is
    Elite
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Pancreatic Cancer
    Dr. Dotan is
    Elite
    . Learn about Pancreatic Cancer.
    See more Pancreatic Cancer experts
  • Distinguished
  • Anal Cancer
    Dr. Dotan is
    Distinguished
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Dotan is
    Distinguished
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Familial Colorectal Cancer
    Dr. Dotan is
    Distinguished
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Familial Pancreatic Cancer
    Dr. Dotan is
    Distinguished
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Gastroesophageal Junction Cancer
    Dr. Dotan is
    Distinguished
    . Learn about Gastroesophageal Junction Cancer.
    See more Gastroesophageal Junction Cancer experts
  • Lynch Syndrome
    Dr. Dotan is
    Distinguished
    . Learn about Lynch Syndrome.
    See more Lynch Syndrome experts
View All 8 Distinguished Conditions
  • Advanced
  • Appendix Cancer
    Dr. Dotan is
    Advanced
    . Learn about Appendix Cancer.
    See more Appendix Cancer experts
  • Fibrolamellar Carcinoma
    Dr. Dotan is
    Advanced
    . Learn about Fibrolamellar Carcinoma.
    See more Fibrolamellar Carcinoma experts
  • Gallbladder Adenocarcinoma
    Dr. Dotan is
    Advanced
    . Learn about Gallbladder Adenocarcinoma.
    See more Gallbladder Adenocarcinoma experts
  • Gallbladder Cancer
    Dr. Dotan is
    Advanced
    . Learn about Gallbladder Cancer.
    See more Gallbladder Cancer experts
  • Experienced
  • Ampullary Cancer
    Dr. Dotan is
    Experienced
    . Learn about Ampullary Cancer.
    See more Ampullary Cancer experts
  • Angiosarcoma
    Dr. Dotan is
    Experienced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Biliary Dyskinesia
    Dr. Dotan is
    Experienced
    . Learn about Biliary Dyskinesia.
    See more Biliary Dyskinesia experts
  • Breast Cancer
    Dr. Dotan is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Esophageal Cancer
    Dr. Dotan is
    Experienced
    . Learn about Esophageal Cancer.
    See more Esophageal Cancer experts
  • Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
    Dr. Dotan is
    Experienced
    . Learn about Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET).
    See more Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) experts
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.